Article

Pioglitazone induced reversible pancytopenia.

Endocrinology Department, Fatih University Hospital, 06510 Ankara Turkey.
Experimental and Clinical Endocrinology &amp Diabetes (impact factor: 1.69). 10/2009; 118(2):96-7. DOI:10.1055/s-0029-1234065 pp.96-7
Source: PubMed

ABSTRACT Pioglitazone is used to improve insulin sensitivity in type 2 diabetes. This group of drugs is usually well tolerated; however, their use may be associated with several adverse effects including edema, weight gain, macular edema and heart failure. Herein we report a patient who developed pancytopenia on the 7th day of oral pioglitazone treatment for the control of diabetes mellitus and fully recovered 6 days after the cessation of this drug. To the best of our knowledge this is the first reported case of pancytopenia induced by pioglitazone therapy.

0 0
 · 
0 Bookmarks
 · 
43 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

6 days
 
7th day
 
adverse effects
 
cessation
 
edema
 
heart failure
 
insulin sensitivity
 
macular edema
 
oral pioglitazone treatment
 
pancytopenia induced
 
Pioglitazone
 
pioglitazone therapy
 
weight gain
 

F Karakurt